Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine.
Glutamate excitotoxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). We report the results of a double blind, placebo controlled, trial using 100 mg of oral daily lamotrigine (3,5-diamino-6-(2,3 dichlorophenyl)-1,2,4-triazine) which inhibits glutamate release. 67 patients were entered and at trial termination of 1.5 years 15 had withdrawn (9 active and 6 placebo) and 12 had died (6 active and 6 placebo). Mean age at entry was 57.5 years for the active and 58.6 years for the placebo groups. Patients were seen at 3 monthly intervals and scored according to neurological deficit based upon age of onset, bulbar and respiratory involvement, ambulation and functional disability. The mean change in clinical scores for the active versus placebo groups over the trial period was 7.1 +/- 3.3 and 9.0 +/- 3.3 respectively (0.05 < p < 0.10). Changes in cortical threshold and MEP/CMAP ratios to magnetic stimulation also did not differ significantly between the two groups. We conclude that lamotrigine in the doses administered does not alter the course of ALS.
Eisen
A
A
Neuromuscular Diseases Unit, Vancouver General Hospital, British Columbia, Canada.
Stewart
H
H
Schulzer
M
M
Cameron
D
D
D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000502:physiology; D004311:Double-Blind Method; D004594:Electrophysiology; D018691:Excitatory Amino Acid Antagonists; D005260:Female; D018698:Glutamic Acid; D006801:Humans; D000077213:Lamotrigine; D008280:Magnetics; D008297:Male; D008875:Middle Aged; D010812:Physical Stimulation; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D018691:Excitatory Amino Acid Antagonists; D014227:Triazines; D018698:Glutamic Acid; D000077213:Lamotrigine